Drug-Eluting Balloons

This channel includes news and new technology innovations for drug-coated balloons (DCB), also referred to as drug-eluting balloons. These are used to treat peripheral and coronary artery lesions and restenosis. The balloons carry an antiproliferative drug that is delivered to the wall of arteries when the balloon is expanded. The drug helps prevent neointimal hyperplasia (scar tissue growth) caused by trauma when the vessel segment is treated for atherosclerotic lesions with balloon angioplasty. DCBs can be used to treat hyperplasia in arteriovenous (AV) access fistulae in dialysis patients, where the vessel undergoes repeated trauma from regular punctures. DCBs also are used to treat in-stent restenosis due to scar tissue proliferation inside stents, which can cause a vessel to occlude.

News | Drug-Eluting Balloons

May 4, 2023 — The first US patient has been enrolled in the SELUTION4SFA Sirolimus DEB study by Dr. Arthur Lee at the Ca ...

Home May 04, 2023
Home
News | Drug-Eluting Balloons

April 28, 2023 — Medtronic today shared additional 36-month data from the IN.PACT AV Access Study, as well as 48-month ...

Home April 28, 2023
Home
Feature | Cardiovascular Business | By Emily Gilbert and Kamran Zamanian, PhD

The European interventional cardiology device market is one of the larger markets in the global space. The market is ...

Home April 24, 2023
Home
News | Drug-Eluting Balloons

March 14, 2023 —MedAlliance has announced enrollment of over 1,000 patients in its ground-breaking SELUTION DeNovo coron ...

Home March 14, 2023
Home
News | Drug-Eluting Balloons

January 27, 2023 — The first US patient has been enrolled at Medstar Washington Hospital Center in the SELUTION4ISR ...

Home January 27, 2023
Home
News | Drug-Eluting Balloons

January 12, 2023 — Selution SLR, MedAlliance’s novel sirolimus-eluting balloon, has received conditional FDA ...

Home January 12, 2023
Home
News | Drug-Eluting Balloons

January 2, 2023 — The U.S. Food and Drug Administration (FDA) has approved the Stellarex 0.035” OTW Drug-coated ...

Home January 02, 2023
Home
News | Drug-Eluting Balloons

November 28, 2022 – BIOTRONIK announced the presentation of one-year results from the investigator ...

Home November 28, 2022
Home
News | VIVA

November 3, 2022 — Medtronic, a global leader in medical technology, today announced the results of two clinical studies ...

Home November 03, 2022
Home
News | Drug-Eluting Balloons

October 28, 2022 —  SELUTION SLR, MedAlliance’s novel sirolimus-eluting balloon, has received FDA Investigational Device ...

Home October 28, 2022
Home
News | Drug-Eluting Balloons

October 18, 2022 — Swiss-based medical technology company MedAlliance has announced it has entered into an agreement ...

Home October 18, 2022
Home
News | Drug-Eluting Balloons

August 23, 2022 — The first US patient has been enrolled in the FDA SELUTION4BTK (Below-the-Knee) clinical trial ...

Home August 23, 2022
Home
News | Drug-Eluting Balloons

July 12, 2022 — Biotronik announced the presentation of two studies on the performance of its drug-coated balloon ...

Home July 12, 2022
Home
News | Drug-Eluting Balloons

June 8, 2022 — The first patient has been enrolled in the FDA IDE BTK (Below-the-Knee) SELUTION4BTK clinical trial ...

Home June 08, 2022
Home
Subscribe Now